NASDAQ:CYAD - Celyad Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$26.90 +0.85 (+3.26 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$26.90
Today's Range$26.84 - $27.80
52-Week Range$25.55 - $64.75
Volume92,849 shs
Average Volume15,048 shs
Market Capitalization$265.56 million
P/E Ratio-7.60
Dividend YieldN/A
Beta1.61

About Celyad (NASDAQ:CYAD)

Celyad logoCelyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Receive CYAD News and Ratings via Email

Sign-up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYAD
CUSIPN/A
Phone321-039-4100

Debt

Debt-to-Equity Ratio0.02
Current Ratio4.58
Quick Ratio4.58

Price-To-Earnings

Trailing P/E Ratio-7.60
Forward P/E Ratio-5.99
P/E GrowthN/A

Sales & Book Value

Annual Sales$4 million
Price / Sales66.38
Cash FlowN/A
Price / CashN/A
Book Value$5.44 per share
Price / Book4.94

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees88
Outstanding Shares9,870,000

Celyad (NASDAQ:CYAD) Frequently Asked Questions

What is Celyad's stock symbol?

Celyad trades on the NASDAQ under the ticker symbol "CYAD."

What price target have analysts set for CYAD?

1 brokers have issued 1-year target prices for Celyad's stock. Their predictions range from $74.00 to $74.00. On average, they expect Celyad's share price to reach $74.00 in the next year. View Analyst Ratings for Celyad.

Who are some of Celyad's key competitors?

Who are Celyad's key executives?

Celyad's management team includes the folowing people:
  • Mr. Michel E. Lussier MS BME, MBA, Co-Founder & Chairman (Age 62)
  • Dr. Christian Homsy M.D., MBA, CEO & Exec. Director (Age 60)
  • Mr. Patrick Jeanmart, Chief Financial Officer & Investor Relations (Age 46)
  • Dr. Jean-Pierre Latere, Chief Operating Officer (Age 43)
  • Mr. Philippe Dechamps, Chief Legal Officer (Age 48)

When did Celyad IPO?

(CYAD) raised $99 million in an initial public offering on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Has Celyad been receiving favorable news coverage?

News headlines about CYAD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celyad earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 50.21 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the next several days.

Who are Celyad's major shareholders?

Celyad's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (4.31%) and Jane Street Group LLC (0.17%). View Institutional Ownership Trends for Celyad.

Which institutional investors are selling Celyad stock?

CYAD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. View Insider Buying and Selling for Celyad.

Which institutional investors are buying Celyad stock?

CYAD stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View Insider Buying and Selling for Celyad.

How do I buy shares of Celyad?

Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celyad's stock price today?

One share of CYAD stock can currently be purchased for approximately $26.90.

How big of a company is Celyad?

Celyad has a market capitalization of $265.56 million and generates $4 million in revenue each year. The company earns $-63,740,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis. Celyad employs 88 workers across the globe.

How can I contact Celyad?

Celyad's mailing address is Rue Edouard Belin 2, Mont-Saint-Guibert C9, 1435. The company can be reached via phone at 321-039-4100.


MarketBeat Community Rating for Celyad (CYAD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Celyad and other stocks. Vote "Outperform" if you believe CYAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celyad (NASDAQ:CYAD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Celyad in the last 12 months. Their average twelve-month price target is $74.00, suggesting that the stock has a possible upside of 175.09%. The high price target for CYAD is $74.00 and the low price target for CYAD is $74.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $74.00$74.00$74.00$74.00
Price Target Upside: 175.09% upside20.92% upside20.92% upside20.92% upside

Celyad (NASDAQ:CYAD) Consensus Price Target History

Price Target History for Celyad (NASDAQ:CYAD)

Celyad (NASDAQ:CYAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Piper Jaffray CompaniesReiterated RatingOverweight$74.00N/AView Rating Details
7/5/2016UBSDowngradeBuy ➝ Neutral$79.00 ➝ $27.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Dividends

Celyad (NASDAQ:CYAD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Celyad (NASDAQ CYAD) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 4.54%
Insider Trading History for Celyad (NASDAQ:CYAD)
Insider Trading History for Celyad (NASDAQ:CYAD)

Celyad (NASDAQ CYAD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Celyad (NASDAQ CYAD) News Headlines

Source:
DateHeadline
BRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global OfferingBRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global Offering
www.reuters.com - May 17 at 10:21 AM
Celyad announces pricing of $47.3 million global offeringCelyad announces pricing of $47.3 million global offering
finance.yahoo.com - May 17 at 10:21 AM
Celyad (CYAD) Lowered to Sell at Zacks Investment ResearchCelyad (CYAD) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 9:24 PM
Zacks: Celyad (CYAD) Given $74.00 Consensus Price Target by BrokeragesZacks: Celyad (CYAD) Given $74.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - May 16 at 7:17 PM
BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business UpdateBRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update
www.reuters.com - May 16 at 10:50 AM
Celyad announces launch of proposed global offeringCelyad announces launch of proposed global offering
finance.yahoo.com - May 16 at 10:50 AM
Celyad Announces First Quarter 2018 Business UpdateCelyad Announces First Quarter 2018 Business Update
finance.yahoo.com - May 16 at 10:50 AM
Celyad -3.3% after announcing 1.8M-unit offeringCelyad -3.3% after announcing 1.8M-unit offering
seekingalpha.com - May 15 at 8:07 PM
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual MeetingCelyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
www.businesswire.com - May 9 at 10:10 AM
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018
feeds.benzinga.com - May 9 at 3:13 AM
Celyad SA (CYAD) Reports Successful Injection of CYAD-01 in First Patients in SHRINK and LINK TrialsCelyad SA (CYAD) Reports Successful Injection of CYAD-01 in First Patients in SHRINK and LINK Trials
www.streetinsider.com - May 4 at 9:57 AM
ValuEngine Upgrades Celyad (CYAD) to "Hold"ValuEngine Upgrades Celyad (CYAD) to "Hold"
www.americanbankingnews.com - May 3 at 7:57 PM
BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link TrialsBRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials
www.reuters.com - May 3 at 10:00 AM
Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK TrialsCelyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials
finance.yahoo.com - May 3 at 10:00 AM
46 Biggest Movers From Friday46 Biggest Movers From Friday
www.benzinga.com - April 30 at 10:52 AM
 Celyad (CYAD) Given Average Recommendation of "Strong Buy" by Analysts Celyad (CYAD) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 29 at 7:54 AM
Celyad up 20% on encouraging data on CAR-T candidate CYAD-01Celyad up 20% on encouraging data on CAR-T candidate CYAD-01
seekingalpha.com - April 28 at 10:43 AM
What Should Investors Know About Celyad SA’s (NASDAQ:CYAD) Growth?What Should Investors Know About Celyad SA’s (NASDAQ:CYAD) Growth?
finance.yahoo.com - April 27 at 3:46 PM
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed ...Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed ...
globenewswire.com - April 27 at 10:48 AM
BRIEF-Celyads CYAD-01 Induced Complete Remission In Relapsed/Refractory AML PatientBRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient
www.reuters.com - April 27 at 10:48 AM
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML PatientHaematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
finance.yahoo.com - April 27 at 10:47 AM
Celyad SA (EBR:CYAD): What’s The Analyst Consensus Outlook?Celyad SA (EBR:CYAD): What’s The Analyst Consensus Outlook?
finance.yahoo.com - April 26 at 10:05 AM
Celyad (CYAD) Downgraded to Hold at BidaskClubCelyad (CYAD) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 19 at 1:56 PM
 Analysts Set $74.00 Target Price for Celyad SA (CYAD) Analysts Set $74.00 Target Price for Celyad SA (CYAD)
www.americanbankingnews.com - April 14 at 5:19 AM
Analyzing Celyad (CYAD) and The CompetitionAnalyzing Celyad (CYAD) and The Competition
www.americanbankingnews.com - April 12 at 11:29 AM
Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018
finance.yahoo.com - April 6 at 10:55 AM
The Global Market for Stem CellsThe Global Market for Stem Cells
www.prnewswire.com - April 3 at 4:00 PM
Global Stem Cells Market 2016-2018 & 2022 & Profiles of Cellular Dynamics International, Celyad, Cytori Therapeutics ...Global Stem Cells Market 2016-2018 & 2022 & Profiles of Cellular Dynamics International, Celyad, Cytori Therapeutics ...
www.benzinga.com - March 29 at 10:42 AM
Zacks: Celyad SA (CYAD) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Celyad SA (CYAD) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - March 27 at 1:14 PM
Zacks: Analysts Set $74.00 Target Price for Celyad SA (CYAD)Zacks: Analysts Set $74.00 Target Price for Celyad SA (CYAD)
www.americanbankingnews.com - March 24 at 11:54 AM
Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018
finance.yahoo.com - March 23 at 9:50 AM
Zacks: Celyad SA (CYAD) Given $74.00 Average Price Target by AnalystsZacks: Celyad SA (CYAD) Given $74.00 Average Price Target by Analysts
www.americanbankingnews.com - March 2 at 7:27 PM
 Celyad SA (CYAD) Given $74.00 Average Target Price by Analysts Celyad SA (CYAD) Given $74.00 Average Target Price by Analysts
www.americanbankingnews.com - February 23 at 5:12 AM
 Celyad SA (CYAD) Receives Consensus Recommendation of "Strong Buy" from Analysts Celyad SA (CYAD) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 1 at 9:22 PM
Zacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by AnalystsZacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by Analysts
www.americanbankingnews.com - January 29 at 1:28 AM
Head to Head Review: Oncobiologics (ONS) and Celyad (CYAD)Head to Head Review: Oncobiologics (ONS) and Celyad (CYAD)
www.americanbankingnews.com - January 19 at 3:14 PM
Critical Comparison: EXACT Sciences (EXAS) & Celyad (CYAD)Critical Comparison: EXACT Sciences (EXAS) & Celyad (CYAD)
www.americanbankingnews.com - December 27 at 1:16 PM
 Celyad SA (CYAD) Given $74.00 Average Target Price by Brokerages Celyad SA (CYAD) Given $74.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 27 at 3:32 AM
Celyad (CYAD) Downgraded by ValuEngine to "Sell"Celyad (CYAD) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 3 at 5:12 PM
Zacks: Analysts Set $74.00 Price Target for Celyad SA (CYAD)Zacks: Analysts Set $74.00 Price Target for Celyad SA (CYAD)
www.americanbankingnews.com - November 28 at 11:24 PM
Celyad to Present at the 29th Annual Piper Jaffray Healthcare ConferenceCelyad to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 21 at 6:01 PM
Celyad: Why Did It Go Down Recently? - Seeking AlphaCelyad: Why Did It Go Down Recently? - Seeking Alpha
seekingalpha.com - November 17 at 11:34 PM
Celyad Announces Third Quarter 2017 Business UpdateCelyad Announces Third Quarter 2017 Business Update
finance.yahoo.com - November 17 at 1:25 PM
NKTRs Pivot Data Pleases Investors, OPHT Catches Eyes, CALA Craters, Wave RisesNKTR's Pivot Data Pleases Investors, OPHT Catches Eyes, CALA Craters, Wave Rises
www.rttnews.com - November 13 at 10:43 PM
 Analysts Set $74.00 Price Target for Celyad SA (CYAD) Analysts Set $74.00 Price Target for Celyad SA (CYAD)
www.americanbankingnews.com - November 11 at 1:28 AM
Zacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by BrokeragesZacks: Celyad SA (CYAD) Given $74.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 7 at 5:32 AM
NovaBay Pharmaceuticals (NBY) and Celyad SA (CYAD) Financial ReviewNovaBay Pharmaceuticals (NBY) and Celyad SA (CYAD) Financial Review
www.americanbankingnews.com - November 4 at 8:22 AM
Edison Issues ADR Update on Celyad (CYAD)Edison Issues ADR Update on Celyad (CYAD)
finance.yahoo.com - October 30 at 6:22 PM
Zacks: Celyad SA (CYAD) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Celyad SA (CYAD) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - October 17 at 10:48 AM
Celyad SA (CYAD) Rating Reiterated by Piper Jaffray CompaniesCelyad SA (CYAD) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - October 9 at 1:22 PM

SEC Filings

Celyad (NASDAQ:CYAD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celyad (NASDAQ:CYAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celyad (NASDAQ CYAD) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.